Literature DB >> 20077000

Medical comorbidities predict mortality in women with a history of early stage breast cancer.

Ruth E Patterson1, Shirley W Flatt, Nazmus Saquib, Cheryl L Rock, Bette J Caan, Barbara A Parker, Gail A Laughlin, Kirsten Erickson, Cynthia A Thomson, Wayne A Bardwell, Richard A Hajek, John P Pierce.   

Abstract

This analysis was conducted to determine whether comorbid medical conditions predict additional breast cancer events and all-cause mortality in women with a history of early stage breast cancer. Women (n = 2,542) participating in a randomized diet trial completed a self-administered questionnaire regarding whether they were currently being treated for a wide variety of diseases (cardiovascular, diabetes, gallbladder, gastrointestinal, arthritis, and osteoporosis) and conditions (high blood pressure, elevated cholesterol level). Height and weight were measured at baseline. Participants were followed for a median of 7.3 years (range 0.8-15.0). Cox regression analysis was performed to assess whether comorbidities predicted disease-free and overall survival; hazard ratio (HR) was the measure of association. Overall, there were 406 additional breast cancer events and 242 deaths. Participants with diabetes had over twofold the risk of additional breast cancer events (HR 2.1, 95% CI: 1.3, 3.4) and mortality (HR 2.5, 95% CI: 1.4, 4.4). The presence of multiple comorbidities did not statistically significantly predict additional breast cancer events. However, compared to no comorbidities, participants with 3 or more comorbidities had a HR of 2.1, 95% CI: 1.3, 3.3 for mortality. In conclusion, type 2 diabetes is associated with poor breast cancer prognosis. Given that 85% of deaths were caused by breast cancer, these findings suggest that multiple comorbidities may reduce the likelihood of surviving additional breast cancer events.

Entities:  

Mesh:

Year:  2010        PMID: 20077000      PMCID: PMC2895945          DOI: 10.1007/s10549-010-0732-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  34 in total

Review 1.  Measurement and impact of comorbidity in older cancer patients.

Authors:  M Extermann
Journal:  Crit Rev Oncol Hematol       Date:  2000-09       Impact factor: 6.312

Review 2.  How to measure comorbidity. a critical review of available methods.

Authors:  Vincent de Groot; Heleen Beckerman; Gustaaf J Lankhorst; Lex M Bouter
Journal:  J Clin Epidemiol       Date:  2003-03       Impact factor: 6.437

Review 3.  Measuring comorbidity in older cancer patients.

Authors:  M Extermann
Journal:  Eur J Cancer       Date:  2000-03       Impact factor: 9.162

4.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

Review 5.  Energy balance and cancer: the role of insulin and insulin-like growth factor-I.

Authors:  R Kaaks; A Lukanova
Journal:  Proc Nutr Soc       Date:  2001-02       Impact factor: 6.297

6.  Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom).

Authors:  P K Verkasalo; H V Thomas; P N Appleby; G K Davey; T J Key
Journal:  Cancer Causes Control       Date:  2001-01       Impact factor: 2.506

7.  Health-related quality of life in women previously treated for early-stage breast cancer.

Authors:  Wayne A Bardwell; Jacqueline M Major; Cheryl L Rock; Vicky A Newman; Cynthia A Thomson; Janice A Chilton; Joel E Dimsdale; John P Pierce
Journal:  Psychooncology       Date:  2004-09       Impact factor: 3.894

8.  Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study.

Authors:  Karin B Michels; Caren G Solomon; Frank B Hu; Bernard A Rosner; Susan E Hankinson; Graham A Colditz; JoAnn E Manson
Journal:  Diabetes Care       Date:  2003-06       Impact factor: 19.112

Review 9.  Neuroendocrinology of aging in the male and female.

Authors:  R J Urban
Journal:  Endocrinol Metab Clin North Am       Date:  1992-12       Impact factor: 4.741

10.  A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study.

Authors:  John P Pierce; Susan Faerber; Fred A Wright; Cheryl L Rock; Vicky Newman; Shirley W Flatt; Sheila Kealey; Vicky E Jones; Bette J Caan; Ellen B Gold; Mary Haan; Kathryn A Hollenbach; Lovell Jones; James R Marshall; Cheryl Ritenbaugh; Marcia L Stefanick; Cynthia Thomson; Linda Wasserman; Loki Natarajan; Ronald G Thomas; Elizabeth A Gilpin
Journal:  Control Clin Trials       Date:  2002-12
View more
  41 in total

Review 1.  A review of cancer in U.S. Hispanic populations.

Authors:  Robert W Haile; Esther M John; A Joan Levine; Victoria K Cortessis; Jennifer B Unger; Melissa Gonzales; Elad Ziv; Patricia Thompson; Donna Spruijt-Metz; Katherine L Tucker; Jonine L Bernstein; Thomas E Rohan; Gloria Y F Ho; Melissa L Bondy; Maria Elena Martinez; Linda Cook; Mariana C Stern; Marcia Cruz Correa; Jonelle Wright; Seth J Schwartz; Lourdes Baezconde-Garbanati; Victoria Blinder; Patricia Miranda; Richard Hayes; George Friedman-Jiménez; Kristine R Monroe; Christopher A Haiman; Brian E Henderson; Duncan C Thomas; Paolo Boffetta
Journal:  Cancer Prev Res (Phila)       Date:  2012-02

2.  Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study.

Authors:  E H Allott; C-K Tse; A F Olshan; L A Carey; P G Moorman; M A Troester
Journal:  Breast Cancer Res Treat       Date:  2014-08-24       Impact factor: 4.872

3.  Obesity and breast cancer survival in ethnically diverse postmenopausal women: the Multiethnic Cohort Study.

Authors:  Shannon M Conroy; Gertraud Maskarinec; Lynne R Wilkens; Kami K White; Brian E Henderson; Laurence N Kolonel
Journal:  Breast Cancer Res Treat       Date:  2011-04-16       Impact factor: 4.872

4.  Sleep duration and breast cancer prognosis: perspectives from the Women's Healthy Eating and Living Study.

Authors:  Catherine R Marinac; Sandahl H Nelson; Shirley W Flatt; Loki Natarajan; John P Pierce; Ruth E Patterson
Journal:  Breast Cancer Res Treat       Date:  2017-02-11       Impact factor: 4.872

5.  Multimorbidity: an issue of growing importance for oncologists.

Authors:  Christine S Ritchie; Elizabeth Kvale; Michael J Fisch
Journal:  J Oncol Pract       Date:  2011-11       Impact factor: 3.840

6.  The psychosocial impact of lymphedema-related distress among breast cancer survivors in the WHEL Study.

Authors:  Sally A Dominick; Loki Natarajan; John P Pierce; Hala Madanat; Lisa Madlensky
Journal:  Psychooncology       Date:  2014-02-26       Impact factor: 3.894

7.  Good glycaemic control is associated with a better prognosis in breast cancer patients with type 2 diabetes mellitus.

Authors:  Yen-Lin Chang; Wayne Huey-Herng Sheu; Shih-Yi Lin; Wen-Shyong Liou
Journal:  Clin Exp Med       Date:  2018-03-23       Impact factor: 3.984

8.  Improving health engagement and lifestyle management for breast cancer survivors with diabetes.

Authors:  Rebecca A Shelby; Caroline S Dorfman; Sarah S Arthur; Hayden B Bosworth; Leonor Corsino; Linda Sutton; Lynda Owen; Alaattin Erkanli; Francis Keefe; Cheyenne Corbett; Gretchen Kimmick
Journal:  Contemp Clin Trials       Date:  2020-04-11       Impact factor: 2.226

9.  Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population.

Authors:  Aruna Kamineni; Melissa L Anderson; Emily White; Stephen H Taplin; Peggy Porter; Rachel Ballard-Barbash; Kathleen Malone; Diana S M Buist
Journal:  Cancer Causes Control       Date:  2012-12-07       Impact factor: 2.506

10.  Exercise after diagnosis and metabolic syndrome among breast cancer survivors: a report from the Shanghai Breast Cancer Survival Study.

Authors:  Ping-Ping Bao; Ying Zheng; Sarah Nechuta; Kai Gu; Hui Cai; Peng Peng; Xiao-Ou Shu; Wei Lu
Journal:  Cancer Causes Control       Date:  2013-07-17       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.